These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32860561)

  • 1. The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
    Beaudry F; Huot P
    J Neural Transm (Vienna); 2020 Oct; 127(10):1343-1358. PubMed ID: 32860561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mGluR
    Kang W; Nuara SG; Bédard D; Frouni I; Kwan C; Hamadjida A; Gourdon JC; Gaudette F; Beaudry F; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2347-2355. PubMed ID: 37410156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the mGlu
    Frouni I; Kwan C; Bédard D; Kang W; Hamadjida A; Nuara SG; Gourdon JC; Huot P
    Psychopharmacology (Berl); 2023 Oct; 240(10):2093-2099. PubMed ID: 37516708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the mGlu
    Frouni I; Kwan C; Nuara SG; Belliveau S; Kang W; Hamadjida A; Bédard D; Gourdon JC; Huot P
    J Neural Transm (Vienna); 2021 Jan; 128(1):73-81. PubMed ID: 33392826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
    Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
    Frouni I; Belliveau S; Maddaford S; Nuara SG; Gourdon JC; Huot P
    Eur J Pharmacol; 2021 Nov; 910():174452. PubMed ID: 34480885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
    Sid-Otmane L; Hamadjida A; Nuara SG; Bédard D; Gaudette F; Gourdon JC; Michaud V; Beaudry F; Panisset M; Huot P
    Eur J Pharmacol; 2020 Apr; 873():172957. PubMed ID: 32004527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
    Hamadjida A; Nuara SG; Bédard D; Frouni I; Kwan C; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Dec; 391(12):1339-1345. PubMed ID: 30088028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT
    Kwan C; Frouni I; Bédard D; Nuara SG; Gourdon JC; Hamadjida A; Huot P
    Exp Brain Res; 2019 Feb; 237(2):435-442. PubMed ID: 30443669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effects of mGluR
    Nuara SG; Gourdon JC; Maddaford S; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Dec; 394(12):2381-2388. PubMed ID: 34550406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
    Huot P; Johnston TH; Lewis KD; Koprich JB; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
    Neuropharmacology; 2014 Jul; 82():76-87. PubMed ID: 24447715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effects of the mGlu
    Nuara SG; Gourdon JC; Huot P
    Pharmacol Rep; 2022 Aug; 74(4):614-625. PubMed ID: 35761013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 5-HT
    Kwan C; Frouni I; Bédard D; Hamadjida A; Nuara SG; Gourdon JC; Huot P
    Eur J Neurosci; 2024 Mar; 59(6):1169-1176. PubMed ID: 37515363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined mGlu
    Nuara SG; Hamadjida A; Kwan C; Bédard D; Frouni I; Gourdon JC; Huot P
    J Neural Transm (Vienna); 2020 Jul; 127(7):1023-1029. PubMed ID: 32246204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mGlu
    Nuara SG; Hamadjida A; Gourdon JC; Huot P
    J Neural Transm (Vienna); 2020 Jul; 127(7):1013-1021. PubMed ID: 32333122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
    Hamadjida A; Nuara SG; Veyres N; Frouni I; Kwan C; Sid-Otmane L; Harraka MJ; Gourdon JC; Huot P
    Psychopharmacology (Berl); 2017 Mar; 234(6):905-911. PubMed ID: 28130646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The highly selective 5-HT
    Hamadjida A; Nuara SG; Bédard D; Gaudette F; Beaudry F; Gourdon JC; Huot P
    Neuropharmacology; 2018 Sep; 139():61-67. PubMed ID: 29969592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
    Hamadjida A; Nuara SG; Gourdon JC; Huot P
    J Neural Transm (Vienna); 2018 Sep; 125(9):1355-1360. PubMed ID: 29247391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of mGlu
    Frouni I; Hamadjida A; Kwan C; Bédard D; Nafade V; Gaudette F; Nuara SG; Gourdon JC; Beaudry F; Huot P
    Neuropharmacology; 2019 Nov; 158():107725. PubMed ID: 31351976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.